SLC5A2 and diabetes mellitus: This systematic review and meta-analysis suggests that SGLT2 inhibitor use may be associated with improved cardiovascular outcomes, particularly reduced mortality and heart failure hospitalization, in cancer patients with diabetes receiving cancer therapies.